Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
12 hedge funds and large institutions have $151K invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
8% less funds holding
Funds holding: 13 → 12 (-1)
17% less capital invested
Capital invested by funds: $182K → $151K (-$30.9K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$19.5K |
| 2 |
VFA
Values First Advisors
Gray,
Tennessee
|
+$1.37K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$543 |
| 4 |
Renaissance Technologies
New York
|
+$504 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$336 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$41K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$1K |
| 3 |
Morgan Stanley
New York
|
-$555 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$13 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VFA
1
Values First Advisors
Gray,
Tennessee
| $46.6K | +$1.37K | +814 | +3% |
|
|
2
Renaissance Technologies
New York
| $41K | +$504 | +300 | +1% |
|
|
FLSM
3
Frazier Life Sciences Management
Palo Alto,
California
| $29.7K | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| $20.1K | +$19.5K | +11,607 | New |
|
|
5
Morgan Stanley
New York
| $7.18K | -$555 | -330 | -7% |
|
6
Osaic Holdings
Scottsdale,
Arizona
| $3.21K | – | – | – |
|
|
7
UBS Group
Zurich,
Switzerland
| $2.3K | +$543 | +323 | +33% |
|
|
8
Fidelity Investments
Boston,
Massachusetts
| $346 | +$336 | +200 | New |
|
|
9
Bank of America
Charlotte,
North Carolina
| $147 | -$13 | -8 | -9% |
|
10
Wells Fargo
San Francisco,
California
| $70 | +$59 | +35 | +700% |
|
|
AA
11
Addison Advisors
Middlebury,
Vermont
| $14 | – | – | – |
|
|
12
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$41K | -22,294 | Closed |
|
|
IA
13
IFP Advisors
Tampa,
Florida
| – | -$1K | -28 | Closed |
|
NBRV Hedge Fund Activity: Q1 2023 in Review
12 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q1 2023, worth a combined $151K — down 17% from $182K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NBRV and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 4 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $19.5K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $41K sold.
- 12 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q1 2023, down from 13 in Q4 2022.
- Funds reported $151K of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q1 2023, down 17% quarter-over-quarter.
- 2 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q1 2023 and 3 closed out, a net change of -1 holder.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q1 2023 was Citadel Advisors, an estimated $19.5K added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q1 2023 was Susquehanna International Group, an estimated $41K sold.
Based on aggregated 13F filings for Q1 2023.